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Glioblastoma multiforme (GBM) is a clinically and pathologically heterogeneous brain tumor.
Previous studies of transcriptional profiling have revealed biologically relevant GBM sub-
types associated with specific mutations and dysregulated pathways. Here, we applied
a modified proteome to uncover abnormal protein expression profile in a MRI-classified
group I GBM (GBM1), which has a spatial relationship with one of the adult neural stem
cell niches, subventricular zone (SVZ). Most importantly, we identified molecular charac-
teristics in this type of GBM that include up-regulation of metabolic enzymes, ribosomal
proteins, and heat shock proteins. As GBM1 often recurs at great distances from the initial
lesion, the rewiring of metabolism, and ribosomal biogenesis may facilitate cancer cells’
growth and survival during tumor progression. The intimate contact between GBM1 and
the SVZ raises the possibility that tumor cells in GBM1 may be most related to SVZ cells. In
support of this notion, we found that markers representing SVZ cells are highly expressed
in GBM1. Emerged findings from our study provide a specific protein expression profile in
GBM1 and offer better prediction or therapeutic implication for this multifocal GBM.
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INTRODUCTION
Glioblastoma multiforme (GBM), a devastating disease with lim-
ited therapeutic options, is a highly aggressive brain cancer char-
acterized by uncontrolled proliferation, resistance to cell death,
robust angiogenesis, and vascular edema. Integrated genomic
analysis has identified mutations in distinct types of GBM includ-
ing (1) TP53 and isocitrate dehydrogenase1 (IDH1) in proneural
tumors; (2) NF1in the Mesenchymal subgroup; (3) histone 3.3
in pediatric GBM; and (4) EGFR amplification in classical GBM
tumor (1). Microarray expression profiling has delineated genes
associated with tumor grade and progression as well as resem-
bling processes to those that regulate neurogenesis (2). Thus, the
stem/progenitor cells existing in the subventricular zone (SVZ) of
adult neurogenic niche are suspected to give rise to GBM. Indeed,
the heterogeneous nature of GBM manifests in mixed cell types
within the tumor, including a subpopulation known as glioma
stem cells (GSC) (3, 4). Additionally, the gene expression signa-
ture of GSC resembles those of embryonic stem cells (ESC) and
neural stem cells (NSCs), suggesting GSC share features with non-
neoplastic stem cells. The similarity among GSC, ESC, and neural
stem cell (NSC) provides insight into their common stem-like
behavior in terms of self-renewal, phenotype, and relevant signal-
ing pathways (3, 5–9). Controversially, a recent report suggested
that this type of brain tumor could also develop through repro-
graming of mature cells into progenitor-like cells by oncogenic
factors (10). Independent of these hypotheses, a previous study by
MRI for the spatial relationship of the contrast enhancing lesion
(CEL) with the SVZ and cortex has revealed that group 1 GBM
(GBM1) contacts the SVZ intimately and recurs at great distances
from the initial lesion (11). Since the SVZ harbors cells with great
proliferative potential and the microenvironment within SVZ is
permissive to growth and proliferation, this neurogenic niche is
suspected to be a vulnerable site for the origin of subtypes of GBM.
Mutation and gene expression profiling hold promise for GBM
classification, but such profiling is not performed routinely in the
clinical setting. Usually, patients with GBM are diagnosed and clas-
sified based on MRI features (11). However, the molecular charac-
teristics underlying MRI-classified GBM, such as SVZ-associated
GBM1, remain to be determined. In this study, we focus on the
identification of aberrant protein expression in GBM1. As GBM1
is known to have recurrent tumors at locations distant from the
initial lesion, we found that Annexin A2, a tumor-associated pro-
tease which plays a critical role in tumor invasion, is abundant
in GBM1. Importantly, several highly expressed proteins in GBM1
are linked to metabolism and ribosomal biogenesis, indicating that
metabolic components are activated to support cancer cell growth
and survival. Additionally, we found that c-Myc oncoprotein is
highly expressed in GBM1. c-Myc is known to regulate cell growth
and proliferation through stimulation of ribosomal biogenesis
(12–16), and perhaps c-Myc overexpression in GBM1 enhances
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rRNA synthesis to drive tumor cell growth. Taken together, as this
malignancy progresses, the growing tumor with increased nutrient
demands must use metabolic reprograming to maintain growth
and proliferation. Our findings suggest the potential to exploit
corrections to cancer metabolism for GBM1 therapy.
RESULTS
To uncover the molecular characteristics of MRI-classified GBM1,
we undertook a proteomic approach to detect aberrant protein
expression specifically in GBM1. GBM1 specimens were provided
from the UCSF Neurosurgery department/brain tumor tissue
core and CHTN/NCI (tumor and control region is depicted in
Figure 1A). A modified version of our Microwave and Magnetic
(M2) proteomics method was employed for these studies to semi-
quantitatively compare relative protein abundance for specimens
from GBM1 vs. normal brain region. Briefly, proteins that were
highly expressed in GBM1 compared to normal brain region were
inferred from the confidence (probability-based Mascot score),
in that top-ranked amino acid sequences could be assigned to
MS/MS spectra of tryptic peptides cleaved from top-ranked pro-
teins. In parallel proteomic analysis, an alternative method by
Arg-C digestion and Orbitrap Elite mass spectrometry was applied
to independent sets of specimens. Proteins identified to be aber-
rantly abundant in GBM1 on the top-ranked list are summarized
in Table 1.
Compelling evidence has shown that human GBM is a hetero-
geneous tumor composed of tumor cells and a portion of cancer
stem cells (also called tumor-initiating cells), which share common
features with normal NSCs. These adult NSCs with astrocyte-
like characteristics in human SVZ display markers of GFAP and
vimentin (17). In support of this notion, we found both GFAP and
vimentin are highly expressed in GBM1 compared to correlated
brain region from normal human specimens through proteomic
screening (Figure 1B; Table 1). In addition, by using western blot
for independent specimens, we further validated that GFAP and
the neuroblast marker – doublecortin (DCX) are highly expressed
in GBM1 (Figure 1C). Consistent with previous study that DCX-
positive cells are abundant at birth but decline rapidly within the
first 2 years of human life (18), we also found that DCX level is very
low in control region (Figure 1C). However, DCX was elevated in
GBM1 specimens (Figure 1C), implicating a potential signature of
GBM1. Although our current result is not direct evidence show-
ing that GBM1 arose from SVZ, notably, GBM1 tumors harbor
undifferentiated SVZ cells. Importantly, proteins with known roles
in energy metabolism and ribosome biogenesis were identified
to be highly expressed in GBM1 compared to correlated normal
brain regions (Table 1; Figure 2). As a growing tumor must meet
energetic and biosynthetic demands to survive environmental
fluctuations in nutrients availability, cancer cells dramatically alter
their metabolic circuitry (19). Thus, these proteins associated with
FIGURE 1 | Experimental strategy and results from proteomic
screening. (A) Schematic diagram depicting the region of GBM1
specimen for proteomic screening. (B) Glial fibrillary acidic protein (GFAP
or E9PAX3_HUMAN), one of the top-ranked proteins shown inTable 1,
was highly expressed in GBM1 vs. normal brain region specimens. The
annotated MS/MS spectrum shown illustrates the amino acid sequence
assignment of product ions to the top-ranked tryptic peptide,
VDFSLAGALNAGFK, which spans amino acid residues 50–63 of GFAP. The
insert shows the amino acid sequence coverage of GFAP with tryptic
peptides observed in bold (and peptide 50–63 underlined). (C) Abundant
level of GFAP and doublecortin (DCX) in independent GBM1 specimens by
western blot.
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Table 1 | Summary of selected highly expressed proteins for GBM1 vs. normal brain region specimens: representative semi-quantitative data
for top-ranked proteins and their top-ranked peptides includes: theTrembl protein database accession symbol (prot_acc), protein description
(prot_desc), probability-based protein database searching score (prot_score) for GBM/normal, peptide score (pep_score), peptide expectation
value (pep_expect), and peptide sequence (pep_seq).
Top-ranked protein evidence Top-ranked peptide evidence
prot_acc prot_desc prot score
(GBM/normal)
pep_score pep_expect pep_seq
A2A3R6_HUMAN 40S ribosomal protein S6 OS=Homo sapiens
GN=RPS6 PE=2 SV=1
56/0 48 3.90E−04 DIPGLTDTTVPR
B5MCT8_HUMAN 40S ribosomal protein S9 OS=Homo sapiens
GN=RPS9 PE=3 SV=1
55/0 55 9.90E−05 LFEGNALLR
C9JNW5_HUMAN 60S ribosomal protein L24 OS=Homo sapiens
GN=RPL24 PE=4 SV=1
88/0 78 1.60E−07 AITGASLADIMAK
E9PIZ3_HUMAN 60S ribosomal protein L8 OS=Homo sapiens
GN=RPL8 PE=4 SV=1
126/0 86 5.40E−08 ASGNYATVISHNPETK
H0Y3A0_HUMAN 60S ribosomal protein L35 (Fragment)
OS=Homo sapiens GN=RPL35 PE=3 SV=1
57/0 57 7.00E−05 VLTVINQTQK
B2R4K7_HUMAN 60S ribosomal protein L6 OS=Homo sapiens
PE=2 SV=1
190/0 68 2.40E−06 HQEGEIFDTEK
H0YHA7_HUMAN 60S ribosomal protein L18 (Fragment)
OS=Homo sapiens GN=RPL18 PE=3 SV=1
205/0 100 2.80E−09 ILTFDQLALDSPK
Q5T8U3_HUMAN 60S ribosomal protein L7a (Fragment)
OS=Homo sapiens GN=RPL7A PE=4 SV=1
30/0 30 2.80E−02 KVVNPLFEK
F8W7C6_HUMAN 60S ribosomal protein L10 OS=Homo sapiens
GN=RPL10 PE=4 SV=1
61/0 61 1.10E−05 FNADEFEDMVAEK
A8MUD9_HUMAN 60S ribosomal protein L7 OS=Homo sapiens
GN=RPL7 PE=3 SV=1
144/0 70 6.70E−06 IVEPYIAWGYPNLK
H0YKD8_HUMAN 60S ribosomal protein L28 OS=Homo sapiens
GN=RPL28 PE=4 SV=1
28/0 29 3.20E−02 QTYSTEPNNLK
E9PKE3_HUMAN Heat shock cognate 71 kDa protein OS=Homo
sapiens GN=HSPA8 PE=3 SV=1
81/0 57 7.20E−05 VEIIANDQGNR
F8WE04_HUMAN Heat shock protein beta1 OS=Homo sapiens
GN=HSPB1 PE=4 SV=1
55/0 50 2.40E−04 VSLDVNHFAPDELTVK
I7HJJ0_HUMAN ADP/ATP translocase 3 (Fragment) OS=Homo
sapiens GN=SLC25A6 PE=3 SV=1
60/0 44 2.40E−03 YFPTQALNFAFK
Q6EZE9_HUMAN Defensin, alpha 3, neutrophil-specific
OS=Homo sapiens GN=DEFA3 PE=4 SV=1
63/0 56 7.70E−05 IPACIAGER
H3BN72_HUMAN Cytochrome c oxidase subunit 4 isoform 1,
mitochondrial OS=Homo sapiens GN=COX4I1
PE=4 SV=1
87/0 46 6.00E−05 SEDFSLPAYMDR
A8K1Y9_HUMAN Guanine nucleotide binding protein (G protein),
alpha activating activity polypeptide, olfactory
type, isoform CRA_b OS=Homo sapiens
GN=GNAL PE=2 SV=1
36/0 36 9.60E−03 LLLLGAGESGK
(Continued)
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Table 1 | Continued
Top-ranked protein evidence Top-ranked peptide evidence
prot_acc prot_desc prot score
(GBM/normal)
pep_score pep_expect pep_seq
Q53HU8_HUMAN Vimentin variant (Fragment) OS=Homo sapiens
PE=2 SV=1
1017/0 108 4.30E−10 EMEENFAVEAANYQDTIGR
E9PAX3_HUMAN Glial fibrillary acidic protein OS=Homo sapiens
GN=GFAP PE=3 SV=1
1737/0 100 5.20E−09 VDFSLAGALNAGFK
H0YMD0_HUMAN Annexin (Fragment) OS=Homo sapiens
GN=ANXA2 PE=3 SV=1
158/0 64 4.00E−06 GVDEVTIVNILTNR
H3BTN5_HUMAN Pyruvate kinase (Fragment) OS=Homo sapiens
GN=PKM PE=3 SV=1
110/28 86 2.60E−08 GADFLVTEVENGGSLGSK
FIGURE 2 | Spectrum of 40S ribosomal protein in GBM1. Two peptides
from the 40S ribosomal protein S8 were identified with high confidence
(less than 1% false discovery rate cut-off) by mass spectrometry. (A) 40S
ribosomal protein S8 peptide sequences (IIDVVYNASNNELVR). (B) 40S
ribosomal protein S8 peptide sequences (ADGYVLEGKELEFYLR). The top
portion of each frame shows the predicted b- and y-ions values (m/z ) for
possible fragments of the identified peptide. Those values highlighted in
red and blue correspond to b-ion and y-ion fragments, respectively, found
in the tandem mass spectrum. The bottom portion of each frame shows
the tandem mass spectrum for each identified peptide. Red and blue
colored peaks correspond to predicted b- and y-ions that were identified in
the spectra.
metabolism and ribogenesis are up-regulated to support enhanced
growth and proliferation in order to survive periods of metabolic
stress. We also found that two heat shock proteins (HSPs) includ-
ing 71 kDa HSPA8 and HSP-beta1 were elevated in our proteomic
screening (Table 1). HSPA8 is induced by different stress signals
to promote cell survival (20), whereas the role of HSP-beta1 in
cancer is not clear. In addition, the tumor-associated proteases
play an important role in tumor migration through degradation
of extracellular matrix (ECM) (21, 22), and we found that Annexin
A2, a member of family of tumor-associated proteases, is highly
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expressed in GBM1 (Table 1). Previous reports in cell culture sys-
tem have demonstrated that knock-down of AnnexinA2 inhibits
glioma cell invasion, suggesting its potential as a GBM1 therapeutic
target (23, 24).
Through our semi-quantitative proteomic approach, abnor-
mal accumulation of several proteins involved in ribosomal bio-
genesis was identified as a signature of GBM1. Taking this into
account, previous studies have demonstrated that c-Myc, a basic
helix-loop-helix-zipper (bHLHZ) transcription factor controls
cellular growth through regulation of ribosomal biogenesis (14,
25–29). Intriguingly, in a parallel study, we found that c-Myc is
expressed in the adult SVZ. The SVZ contains slowly dividing
NSCs, known as type B cells, with astrocyte-like morphology.
These type B cells give rise to transit-amplifying C cells, which
then generate immature neuroblasts (A cells). These neuroblasts
coalesce in the rostral migratory stream (RMS) and then gener-
ate interneurons in the olfactory bulb (30, 31). In adult mouse
SVZ, the majority of c-Myc expression co-localizes with Mash1
and DCX, which label transit-amplifying C cells and neuroblasts,
respectively (Figure 3). Anti-mitotic treatment via the infusion of
cytosine-β-d-arabinofuranoside (Ara-C) into adult brain elimi-
nates these fast dividing progenitors and neuroblasts in the SVZ
but leaves slowly dividing stem cells (B cells) unaffected (32, 33).
We applied this treatment to validate the c-Myc expression pat-
tern in SVZ. Notably, the population of c-Myc positive cells was
substantially diminished after Ara-C treatment (Figures 3F,G).
Because the Ara-C experiment cannot be performed in human or
non-human primates, we applied this treatment in adult mouse
brain to reveal that c-Myc is highly expressed in DCX-positive
population within SVZ, which has intimate contact with GBM1
tumor.
This intriguing finding in mice and the fact that c-Myc is
involved in etiology of different types of cancer (34, 35) prompted
us to examine whether c-Myc is involved in tumors associated with
this germinal niche. To this end, we examined c-Myc abundance
in independent specimens from GBM1 and different groups of
MRI-classified GBM. We found elevated c-Myc levels specifically
in GBM1 (Figures 4A,B). The Myc protein family is comprise
of C-, N-, and L-Myc (36–40). However, we did not find over-
expression of N-myc and L-myc in GBM1 (data not shown),
suggesting c-Myc has a distinct role in GBM1 tumorigenesis.
As GBM1 tumors contain undifferentiated SVZ cells including
DCX-positive neuroblasts (Figure 1C), we further showed that
c-Myc is abundant in the DCX-positive population in GBM1
FIGURE 3 | c-Myc is expressed in the SVZ cell lineages. (A, B) c-Myc
staining in SVZ (20×, coronal section); (C–E) Double labeling of c-Myc (red)
and NSC marker – GFAP (C) as well as other lineage-specific markers showed
c-Myc co-expressing with Mash1 (D), and DCX (E). Double-labeled cells were
marked by arrows. LV: lateral ventricle; Str: striatum (12µ coronal sections;
40× oil; scale bar=50µm). Anti-mitotic treatment abolished most of c-Myc
expressing cells after Ara-C treatment; (F, G) Indicating c-Myc is highly
expressed in progenitors and neuroblasts in SVZ.
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FIGURE 4 | c-Myc level is elevated in type I GBM. Western blot
analysis shows elevated levels of c-Myc in independent sets of GBM1
specimens when compared to other types of GBM (groups II, III, and
IV) and control tissue specimens. (A, B) Control specimens were from
non-cancer donors that were regional and age matched to the MRI
characterized GBM specimens. γ-tubulin was used as internal control.
(C) c-Myc level is abundant in DCX-enriched population from GBM1
specimen.
specimen (Figure 4C), offering a specific protein expression profile
for the putative cancer initiating cells. Since GBM1 has multi-
focal phenotype and c-Myc is preferentially expressed in SVZ
cells with migratory potential, overexpression of c-Myc may play
a role in facilitating tumor growth and migration specifically
for GBM1.
DISCUSSION
Studies depicting the mechanism of glioma formation have been
hampered by the fact that GBM is a dynamic disease. In this
study, our primary goal is to identify the molecular character-
istics of MRI-classified group I GBM (GBM 1) through proteomic
approach. Ultimately, these findings would offer a better idea for
prediction or potential treatment of GBM1. We found that tumor-
associated protease, AnnexinA2 critical in tumor invasion is highly
expressed in GBM1. This finding supports the notion of recur-
rent GBM1 tumors that migrate great distances from the initial
lesions. The elevated level of AnnexinA2 could potentially pre-
dict if tumors are going to be more invasive. Additionally, two
HSPs, HSPA8 and HSP-beta1 were found to be elevated in GBM1
from our screening. Given that HSPA8 are induced by many
different stress signals to promote cell survival in adverse patholog-
ical conditions, such as cancers (20), perhaps, anticancer therapy
by targeting HSPA8 in GBM1 may be an option as well. While
HSP-beta1 is known as estrogen-induced HSP involved in stress
resistance (20, 41), its connection with GBM remains unknown.
We have interest to explore its roles in GBM in future studies. Fur-
thermore, we found that a number of metabolic enzymes and
ribosomal proteins are aberrantly accumulated in GBM1. Our
results imply that amplification of proteins involved in metabo-
lism and ribogenesis could participate, at least in part, to facilitate
tumor growth. Consequently, this metabolic reprograming may
allow cancer cells to survive environmental fluctuations, such as
deficiency of nutrients. Therefore, therapies focused on control-
ling the abnormal metabolic circuitry and ribosomal biogenesis
may be an option for treatment of GBM1.
Previously, MRI-classified GBM localizations have provided
the majority of evidence demonstrating the intimate association
between GBM1 and SVZ (11). Although our current results do
not directly address whether SVZ cells give rise to GBM1, mark-
ers representing neural stem cell trait were found to be abundant
in GBM1 specimens. Our finding highlights that GBM1 contains
undifferentiated NSCs and neuroblasts potentially from the SVZ.
Intriguingly, c-Myc was found to be abundant in the neuroblast-
positive population in GBM1 specimen, suggesting that part of
SVZ cells with high levels of c-Myc may be prone to transform
in GBM1. Future experiments by using in vivo mouse model for
fine-tuning c-Myc levels in the SVZ will address this speculation.
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In conclusion, emerged findings from our study provide cellular
components for specific classification and better prediction for
this multifocal GBM, as well as reveal potential pathways and
metabolites involved in GBM1 that we will focus on in future
studies.
MATERIALS AND METHODS
MICROWAVE AND MAGNETIC (M2) SAMPLE PREPARATION
Protein lysate was extracted from cells using the RIPA lysis
Buffer, the supernatant was collected followed by centrifugation
at 14,000× g for 15 min at 4°C and stored at −80°C until fur-
ther use. Protein concentration was determined using Invitrogen
EZQ Protein Quantitation Kit (Invitrogen, Grand Island, NY). C8
magnetic beads (BcMg, Bioclone Inc.) were used in this study.
Briefly, 50 mg of beads were suspended in 1 ml of 50% methanol.
Immediately before use, 100µL of the beads were washed three
times with equilibration buffer [200 mM NaCl, 0.1% trifluo-
roacetic acid (TFA)]. Protein lysate (25–100µg at 1µg/µL) was
mixed with pre-equilibrated beads and one-third sample binding
buffer (800 mM NaCl, 0.4% TFA) by volume. The mixture was
incubated at room temperature for 5 min followed by removing
the supernatant. The beads were washed twice with 150µL of
40 mM triethylammonium bicarbonate (TEAB), and then 150µL
of 10 mM dithiothreitol (DTT) was added followed by microwave
heating for 10 s. DTT solution was then removed and 150µL of
50 mM iodoacetamide (IAA) was added followed by microwave
heating for 10 s. Next, beads were washed twice with 150µL
of 40 mM TEAB and resuspended in 150µL of 40 mM TEAB.
In vitro proteolysis was performed with 4µL of trypsin in a
1:25 trypsin-to-protein ratio (stock= 1µg/µL in 50 mM acetic
acid) and microwave heated for 20 s in triplicate. The super-
natant was transferred to a new tube for immediate use or stored
at −80°C. In this work, released tryptic peptides from digested
protein lysates were analyzed by capillary liquid chromatography-
Fourier-transform-tandem mass spectrometry (LC/FT/MS/MS)
with protein database searching without isobaric labeling.
CAPILLARY LIQUID
CHROMATOGRAPHY-FOURIER-TRANSFORM-TANDEMMASS
SPECTROMETRY WITH PROTEIN DATABASE SEARCHING
Capillary LC/-FT-MS/MS was performed with a splitless nanoLC-
2D pump (Eksigent, Livermore, CA, USA), a 50µm-i.d. col-
umn packed with 7 cm of 3µm-o.d. C18 particles, and a hybrid
linear ion trap-Fourier-transform tandem mass spectrometer
(LTQ-ELITE; ThermoFisher, San Jose, CA, USA) operated with a
lock mass for calibration. The reverse-phase gradient was 2–62%
of 0.1% formic acid (FA) in acetonitrile over 60 min at 350 nL/min.
For unbiased analyses, the top six most abundant eluting ions were
fragmented by data-dependent HCD with a mass resolution of
120,000 for MS and 15,000 for MS/MS and probability-based
protein database searching of MS/MS spectra against the Trembl
protein database (December 2012 release; 111,137 human pro-
tein sequences) with a 10-node MASCOT cluster (ver. 2.3.02,
Matrix Science, London, UK) with the following search crite-
ria: peak picking with Mascot Distiller; 10 ppm precursor ion
mass tolerance, 0.8 Da product ion mass tolerance, three missed
cleavages, trypsin, carbamidomethyl cysteines as a static modifica-
tion, oxidized methionines and deamidated asparagines as variable
modifications, and an ion score threshold of 20. The MASCOT
score for a peptide is amino acid sequence-specific. According to
the Matrix Science, reported score is−10Log(P). During a search,
if 1500 peptides fell within the mass tolerance window about the
precursor mass, and the significance threshold was chosen to be
0.05, this would translate into a score threshold as cut-off.
ALTERNATIVE PROTEOMEWITH ARG-C DIGESTION AND ORBITRAP
ELITE MASS SPECTROMETER FOR INDEPENDENT SPECIMENS
Five microliters of sample was added to an equal volume of
100 mM ammonium bicarbonate and 200 ng of endoproteinase
Arg-C was added. Proteolytic digestion was carried out overnight
in a 37°C waterbath. Approximately 1µg of digested material was
directly injected (no trap) onto a ThermoScientific nanoEasy LC
coupled to a ThermoScientific Orbitrap Elite mass spectrometer.
Peptide separations were performed on a reversed-phase column
(75µm× 250 mm) packed with Magic C18AQ (5µm, 100Å resin;
Michrom Bioresources, Auburn, CA, USA) directly mounted on
the electrospray ion source. A 60-min gradient from 2 to 40%
acetonitrile in 0.1% FA at a flow rate of 300 nL/min was used
for chromatographic separations. A spray voltage of 2250 V was
applied to the electrospray tip and the Orbitrap Elite instrument
was operated in the data-dependent mode, switching automati-
cally between MS survey scans in the Orbitrap (AGC target value
1,000,000, resolution 120,000, and injection time 250 ms) and
MS/MS spectra acquisition in the linear ion trap (AGC target
value of 10,000 and injection time 100 ms), HCD detected in the
Orbitrap (AGC target value of 50,000, resolution 15,000, and injec-
tion time 250 ms), and ETD detected in the Orbitrap (AGC target
value of 50,000, 15,000 resolution, and injection time 250 ms). The
three most intense ions from the Fourier-transform (FT) full scan
were selected for fragmentation in the linear ion trap by collision-
induced dissociation with normalized collision energy of 35%,
fragmentation in the HCD cell with normalized collision energy
of 35%, and ETD with 100 ms activation time. Selected ions were
dynamically excluded for 30 s. Data analysis was performed using
Proteome Discoverer 1.3 (Thermo Scientific, San Jose, CA, USA).
The data were searched against IPI Human version 3.87 (Interna-
tional Protein Index) database. ArgC was set as the enzyme with
maximum missed cleavages set to two. The precursor ion tolerance
was set to 10 ppm and the fragment ion tolerance was set to 0.8 Da.
All search results were run through Peptide Validator for scoring.
A total of six GBM specimens and five controls obtained from
UCSF and CHTN/NCI had been analyzed by proteome. Because
GBM1 specimens were located in temporal lobe close-by SVZ, we
had three normal controls from temporal region near SVZ (n= 3).
Since GBM1 is an infiltrating tumor, we also had normal control
regions from temporal part near hippocampus (n= 1) and from
frontal lobe (n= 1) used for proteomic screening. The experi-
mental materials involving human specimens are approved by the
Institutional Review Board (IRB) before starting research.
CONFOCAL IMAGING
Brains were OCT embedded after trans-cardial perfusion/fix, and
then 12µm frozen sections were processed for immunostaining
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with antibodies against DCX (Cell Signaling #4604; 1:500),
Glial Fibrillary Acidic Protein (GFAP), clone GA5 (Millipore
#MAB3402, Lot#1993774; 1:500), NeuN (Millipore #MAB377;
1:1000), MASH1 (Abcam #ab38556; 1:500), and c-Myc (Epitomics
#S1242; 1:500). Fluorescent labeling with secondary antibodies
AlexaFIuor 488 (Molecular Probes, dilution 1:1000) and Alexa-
Fluor 594 (Molecular Probes 1:1000) were acquired under Zeiss
LSM 510 confocal microscope.Vectashield with DAPI (Vector Lab-
oratories Ltd., # H-1200) was used for mounting medium and
counter stain.
WESTERN BLOT ANALYSIS OF HUMAN BRAIN TISSUE SAMPLES
By using Glass Tenbroeck Tissue Grinder, cross sections of snap-
frozen brain tissue samples were homogenized in 1 ml Buffer A
with 1× protease inhibitor to extract cytoplasmic proteins. The
resulting pellets were further homogenized in 1 ml RIPA buffer
containing 1× protease inhibitor to isolate nuclear fraction. The
total protein concentrations in cytoplasmic and nuclear frac-
tions were quantified by Bradford assay (Bio-Rad). For western
blot, equal amount of protein from normal or GBM specimens
were denatured in final 1× SDS stop buffer and subjected to
SDS-PAGE for western blot analysis with antibody against c-Myc
(Ab5, Thermo Scientific #MS1054; 1:1000) and γ-tubulin (Sigma
#T5326; 1:1000). Subsequently, HRP-conjugated secondary IgG
(Cell Signaling; 1:5000) and enhanced chemiluminescence kit
(ECL plus; GE) were used for detection.
ARA-C ANTI-MITOTIC TREATMENT
Anti-mitotic (2% Ara-C in 0.9% saline) or control solution
(0.9% saline) was infused at the pial surface of the brain via an
infusion cannula attached to a miniosmotic pump (Alzet, flow
rate of 0.5µL/h). Pumps were installed by following stereotaxic
coordinates (anterior: 0, lateral: 1.1 relative to bregma, and 0 at
the pial surface). After 7 days anti-mitotic treatment, mice were
euthanized at day 0 post-Ara-C by trans-cardial perfusion with
phosphate buffered saline (PBS) and 4% paraformaldehyde (PFA).
Brains were then post-fixed overnight in 4% PFA and sunk in 30%
sucrose prior to cryosectioning at 12µ for immunostaining and
imaging. All mouse experiments were approved by the guidelines
of the Institutional Animal Care and Use Committee of the Uni-
versity of Texas at San Antonio, Fred Hutchinson Cancer Research
Center (FHCRC), and University of California at San Francisco.
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